TY - JOUR
T1 - VT-1161 protects immunosuppressed mice from Rhizopus arrhizus var. arrhizus infection
AU - Gebremariam, Teclegiorgis
AU - Wiederhold, Nathan P.
AU - Fothergill, Annette W.
AU - Garvey, Edward P.
AU - Hoekstra, William J.
AU - Schotzinger, Robert J.
AU - Patterson, Thomas F.
AU - Filler, Scott G.
AU - Ibrahim, Ashraf S.
N1 - Funding Information:
This work was supported by Public Health Service contract HHSN272201000038I (NIH task order A13) and grant R01 AI063503. Research described in the manuscript was partly conducted at the research facilities of the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. VT-1161 powder was provided by Viamet Pharmaceuticals, Inc. Plasma concentrations were determined at OpAns, LLC (Durham, NC).
Publisher Copyright:
© 2015, American Society for Microbiology. All Rights Reserved.
PY - 2015/12/1
Y1 - 2015/12/1
N2 - We studied the efficacy of the investigational drug VT-1161 against mucormycosis. VT-1161 had more potent in vitro activity against Rhizopus arrhizus var. arrhizus than against R. arrhizus var. delemar. VT-1161 treatment demonstrated dose-dependent plasma drug levels with prolonged survival time and lowered tissue fungal burden in immunosuppressed mice infected with R. arrhizus var. arrhizus and was as effective as high-dose liposomal amphotericin B treatment. These results support further development of VT-1161 against mucormycosis.
AB - We studied the efficacy of the investigational drug VT-1161 against mucormycosis. VT-1161 had more potent in vitro activity against Rhizopus arrhizus var. arrhizus than against R. arrhizus var. delemar. VT-1161 treatment demonstrated dose-dependent plasma drug levels with prolonged survival time and lowered tissue fungal burden in immunosuppressed mice infected with R. arrhizus var. arrhizus and was as effective as high-dose liposomal amphotericin B treatment. These results support further development of VT-1161 against mucormycosis.
UR - http://www.scopus.com/inward/record.url?scp=84954496267&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84954496267&partnerID=8YFLogxK
U2 - 10.1128/AAC.01437-15
DO - 10.1128/AAC.01437-15
M3 - Article
C2 - 26369977
AN - SCOPUS:84954496267
VL - 59
SP - 7815
EP - 7817
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
SN - 0066-4804
IS - 12
ER -